Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Lex Bakker Biography and Net Worth

SVP of Merus

Lex Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA). Prior to joining Merus, Lex worked at Crucell NV, where he directed the preclinical and clinical development of a human antibody combination for rabies post-exposure prophylaxis.

How do I contact Lex Bakker?: The corporate mailing address for Mr. Bakker and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Lex Bakker's contact information.
Has Lex Bakker been buying or selling shares of Merus?: Lex Bakker has not been actively trading shares of Merus within the last three months. Most recently, Lex Bakker sold 3,860 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $21.05, for a transaction totalling $81,253.00. Learn More on Lex Bakker's trading history.
Who are Merus' active insiders?: Merus' insider roster includes Lex Bakker (SVP), Kruif de Kruif (SVP), Sven Lundberg (President, Chief Executive Officer, Executive Director), and Peter Silverman (EVP, Chief Operating Officer, & General Counsel). Learn More on Merus' active insiders.
Are insiders buying or selling shares of Merus?: In the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 47,376 shares worth more than $1,969,643.70. The most recent insider tranaction occured on June, 27th when COO Peter B. Silverman sold 10,000 shares worth more than $600,000.00. Insiders at Merus own 4.6% of the company. Learn More about insider trades at Merus.
Information on this page was last updated on 6/27/2024.

Lex Bakker Insider Trading History at Merus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2021	Sell	3,860	$21.05	$81,253.00

Lex Bakker Buying and Selling Activity at Merus

Merus Company Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Today's Range

Now: $52.27

$51.12

$52.83

50 Day Range

MA: $51.03

$47.19

$54.50

2 Week Range

Now: $52.27

$22.01

$61.61

Volume

139,939 shs

Average Volume

684,122 shs

Market Capitalization

$3.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

This company will win the AI race

From Porter & Company | Ad